Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 213 participants.
Also called NCT03006770
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 213 participants
- Sponsor
- Pluristem Ltd.
- Registry
-
NCT03006770
-
- Other papers using this trial's data
- PACE: randomized, controlled, multicentre, multinational, phase III study of PLX-PAD for critical limb ischaemia in patients unsuitable for revascularization: randomized clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Bulgaria, Czechia, Germany, Hungary, Israel, North Macedonia, Poland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03006770. Randomized; double masking; primary purpose treatment. Start 2017-05-22 (actual); primary completion 2021-03-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
- Condition
- Critical Limb Ischemia (CLI)
- Intervention (Biological)
- PLX-PAD
- Intervention (Biological)
- Placebo
- Lead sponsor
- Pluristem Ltd.
Record details
- Record id
cardio:ct-nct03006770- Content hash
546f28b55fe629416d2f76b7c1ef90a145b85ec13e6ad95239af260b4ae31ca7